Search Result

Results for "

interface

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (1) Bcl-2 Family (1) Biochemical Assay Reagents (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) ERK (2) Filovirus (1) G-quadruplex (1) GABA Receptor (2) iGluR (2) nAChR (3) Notch (1) Parasite (1) PD-1/PD-L1 (1) Phosphatase (1) Phospholipase (1) RAD51 (1) Sodium Channel (1) TAM Receptor (1) TRP Channel (2) WDR5 (1)
By Research Areas:	Cancer (15) Infection (2) Inflammation/Immunology (2) Neurological Disease (10)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3654

α-Conotoxin S IA	nAChR	Neurological Disease
α-Conotoxin SIA is a selective nicotinic acetylcholine receptor (nAChR) antagonist with high affinity for the muscle nAChR. α-Conotoxin SIA preferentially targets the α/δ interface of the muscle nAChR in mouse muscle. In contrast, for Torpedo nAChR, α-Conotoxin SIA has a much higher affinity for the α/γ than for the α/δ interface .

HY-136607

DiAzK

Others Others

DiAzK is a bifunctional amino acid. DiAzK can be inserted into almost any protein interface with minimal structural perturbation using genetic code expansion .

DiAzK	Others	Others
DiAzK is a bifunctional amino acid. DiAzK can be inserted into almost any protein interface with minimal structural perturbation using genetic code expansion .

HY-146812

DIZ-3	G-quadruplex	Cancer
DIZ-3 is a selective multimeric G4 ligand based on a G4-ligand-dimerizing strategy. DIZ-3 intercalates into the G4-G4 interface, stabilizing the higher-order structure. DIZ-3 induces cell cycle arrest and apoptosis, and thus inhibits cell proliferation in alternative lengthening of telomere (ALT) cancer cells .

HY-N0347

17α-Hydroxyprogesterone acetate
17α-Hydroxyprogesterone acetate possesses progestational activity. 17α-Hydroxyprogesterone acetate has antiinflammatory effects at the murine maternal-fetal interface .

HY-P2931

Triosephosphate isomerase TPI	Endogenous Metabolite	Others
Triosephosphate isomerase (TPI) is a glycolytic enzyme. Triosephosphate isomerase fast interconverts dihydroxyacetone phosphate and D: -glyceraldehyde-3-phosphate, its catalytic site is at the dimer interface .

HY-Y1422

Triacylglycerol lipase
Triacylglycerol lipase is an enzyme that preferentially hydrolyzes the outer links of triacylglycerols and acts only on the water-lipid interface. Pancreatic triacylglycerol lipase is the single most important determinant of lipid absorption .

HY-W041994

GMBS	Biochemical Assay Reagents	Cancer
GMBS is a heterobifunctional cross-linker. GMBS can be used in chemical cross-linking of proteins coupled with mass spectrometry (CXMS) to study protein folding and to map the interfaces between interacting proteins .

HY-131941

SJM-3	GABA Receptor	Neurological Disease
SJM-3 is a positive allosteric modulator of different isoforms of the GABAA receptor. SJM-3 binds at the high-affinity benzodiazepine binding site at the α+/γ- subunit interface .

HY-P2203A

SAHM1 TFA	Notch
SAHM1 TFA is a Notch pathway inhibitor. SAHM1 TFA stabilizes hydrocarbon-stapled alpha helical peptide. SAHM1 TFA targets the protein-protein interface and prevents Notch complex assembly.

HY-128595

MT-4	Others	Cancer
MT-4 blocks the TG2/FN complex at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum .

HY-162119

PRL-IN-1	Phosphatase	Cancer
PRL-IN-1 (compound 43) is a phosphatase of regenerating liver (PRL) inhibitor that directly binds the PRL1 trimer interface and obstructs PRL1 trimerization. PRL-IN-1 shows potent anticancer activities .

HY-101093

CA-170 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .

HY-107198

(2S)-6-Prenylnaringenin 1 Publications Verification	GABA Receptor	Neurological Disease
(2S)-6-Prenylnaringenin is the most efficient compound in forebrain. (2S)-6-Prenylnaringenin acts as a GABA_A positive allosteric modulator at α+β- binding interface .

HY-125098

Illudin S	DNA Alkylator/Crosslinker Apoptosis	Infection Cancer
Illudin S, a cytotoxic Illudin, is a natural sesquiterpene with strong anti-tumour and antiviral activities. Illudin S has genotoxic activities. Illudin S blocks the G1-S phase interface of the cell cycle in human leukemia cells .

HY-122571

Retro-2	Filovirus Parasite Autophagy	Infection Cancer
Retro-2 is a selective inhibitor of retrograde protein trafficking at the endosome-trans-Golgi network interface. Retro-2 is an ebolavirus (EBOV) infection inhibitor with an EC₅₀ of 12.2 µM in HeLa cells. Retro-2 induces cell autophagy .

HY-122627

CLZ-8	Bcl-2 Family Apoptosis	Cancer
CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a K_i of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells .

HY-111550

Bragsin2 1 Publications Verification	Others	Cancer
Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor BRAG2 inhibitor, with an IC₅₀ of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase. Bragsin2 affects breast cancer stem cells .

HY-W099642

Trimethyloctylammonium bromide Trimethyl-n-octylammonium bromide	Biochemical Assay Reagents	Others
Trimethyloctylammonium bromide (TOAB) is used as a surfactant and phase transfer catalyst in various chemical reactions. TOAB can be used in the synthesis of nanomaterials due to its ability to selectively transfer ions across interfaces and as a surfactant in the production of emulsions and foams. It is valued for its amphiphilic properties, which allow it to interact with water and oils, stabilizing and dispersing mixtures.

HY-124066

RU-302	TAM Receptor	Cancer
RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC₅₀in cell assays, and suppresses lung cancer tumor growth .

HY-153916

TCRS-417 T417	Others	Neurological Disease Inflammation/Immunology Cancer
TCRS-417 (T417) is a small molecule compound capable of docking to the interface between PBX1 and its cognate DNA target sequence, effectively interfering with PBX1-DNA interaction. TCRS-417 can be used in the research of cancer, developmental disorders, inflammatory disorders, autoimmune diseases or neurodegenerative diseases .

HY-125986

GK187	Phospholipase	Neurological Disease
GK187 is a potent and selective Group VIA calcium-independent phospholipase A₂ (GVIA iPLA₂) inhibitor with an X_I(50) value of 0.0001. GK187 can be used for researching various neurological disorders . ^{[The X_I(50) is the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50%.]}

HY-15317

RI-1 4 Publications Verification	RAD51	Cancer
RI-1 is a RAD51 inhibitor, with IC₅₀s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells .

HY-P5149

αC-Conotoxin PrXA αC-PrXA	nAChR	Neurological Disease
αC-Conotoxin PrXA is a paralytic peptide neurotoxin and a competitive nAChR antagonist, with IC₅₀s of 1.8 nM (α1β1εδ, adult) and 3.0 nM (α1β1γδ, fetal), respectively. αC-Conotoxin PrXA competes with α-bungarotoxin at the α/δ and α/γ subunit interfaces of the nAChR, shows high specificity against neuromuscular nAChR .

HY-126214

JH-RE-06 1 Publications Verification	DNA/RNA Synthesis	Cancer
JH-RE-06, a potent REV1-REV7 interface inhibitor (IC₅₀=0.78 μM; K_d=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .

HY-148817

WDR5-0102	WDR5	Cancer
WDR5-0102 is an inhibitor targeting WDR5-MLL1 interface (K_dis=7 μM, K_d=4 μM). WDR5-0102 suppresses MLL1 HMT activity, but not human H3K4 methyltransferase SETD7 and six other HMTs: G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5 .

HY-P1411

Psalmotoxin 1 1 Publications Verification PcTx1; Psalmopoeus cambridgei toxin-1	Sodium Channel Apoptosis	Neurological Disease Cancer
Psalmotoxin 1 (PcTx1) is a protein toxin that can bind at subunit-subunit interfaces of acid-sensing ion channel 1a (ASIC1a). Psalmotoxin 1 is a potent and slective ASIC1a inhibitor (IC₅₀: 0.9 nM) by increasing the apparent affinity for H ⁺ of ASIC1a. Psalmotoxin 1 can induce cell apoptosis, also inhibits cell migration, proferliration and invasion of cancer cells. Psalmotoxin 1 can be used in the research of cancers, or neurological disease .

HY-136258

nAChR agonist CMPI hydrochloride	nAChR	Neurological Disease
nAChR agonist CMPI hydrochloride is a potent and selective positive allosteric modulator (PAM) of nAChR containing a α4:α4 subunit interface. nAChR agonist CMPI hydrochloride enhances the response of (α4)₃(β2)₂ nAChR to ACh (10 µM) with an EC₅₀ of 0.26 µM. nAChR agonist CMPI hydrochloride has potential for the research of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity .

HY-139192

NMDAR/TRPM4-IN-2	iGluR TRP Channel ERK	Neurological Disease
NMDAR/TRPM4-IN-2 (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. NMDAR/TRPM4-IN-2 shows neuroprotective activity. NMDAR/TRPM4-IN-2 prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC₅₀ of 2.1 μM. NMDAR/TRPM4-IN-2 protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .

HY-139192A

NMDAR/TRPM4-IN-2 free base	iGluR TRP Channel ERK	Neurological Disease
NMDAR/TRPM4-IN-2 free base (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. NMDAR/TRPM4-IN-2 free base shows neuroprotective activity. NMDAR/TRPM4-IN-2 free base prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC₅₀ of 2.1 μM. NMDAR/TRPM4-IN-2 free base protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .

Cat. No.	Product Name

HY-L0119V

Asinex PPI Pre-Plated Library	3,253 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.

Asinex PPI Pre-Plated Library

3,253 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.

HY-L110

Cyclic Peptide Library	84 compounds
Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs. MCE offers a unique collection of 84 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cyclic Peptide Library

84 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 84 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

HY-L109

Protein-protein Interaction Inhibitor Library	576 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 576 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Protein-protein Interaction Inhibitor Library

576 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 576 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Trimethyloctylammonium bromide Trimethyl-n-octylammonium bromide	Biochemical Assay Reagents
Trimethyloctylammonium bromide (TOAB) is used as a surfactant and phase transfer catalyst in various chemical reactions. TOAB can be used in the synthesis of nanomaterials due to its ability to selectively transfer ions across interfaces and as a surfactant in the production of emulsions and foams. It is valued for its amphiphilic properties, which allow it to interact with water and oils, stabilizing and dispersing mixtures.

Triosephosphate isomerase TPI	Biochemical Assay Reagents
Triosephosphate isomerase (TPI) is a glycolytic enzyme. Triosephosphate isomerase fast interconverts dihydroxyacetone phosphate and D: -glyceraldehyde-3-phosphate, its catalytic site is at the dimer interface .

Cat. No.	Product Name	Target	Research Area